Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$15.72
-0.84-5.07%
At close: -
$15.70
-0.02-0.13%
After Hours: 7:51 PM EDT
Comments
Loading...
Cormedix Analyst Ratings and Price Targets | NASDAQ:CRMD | Benzinga
Cormedix Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Cormedix Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
D. Boral Capital
RBC Capital
RBC Capital
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Cormedix
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2025 | Buy Now | — | Needham | Serge Belanger67% | $15 → $20 | Maintains | Buy | Get Alert |
| 06/23/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert51% | $15 → $15 | Maintains | Buy | Get Alert |
| 06/20/2025 | Buy Now | — | RBC Capital | Leonid Timashev42% | $13 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 05/07/2025 | Buy Now | — | Needham | Serge Belanger67% | $12 → $15 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert51% | $15 → $15 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | — | Needham | Serge Belanger67% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert51% | $15 → $15 | Maintains | Buy | Get Alert |
| 03/26/2025 | Buy Now | — | RBC Capital | Gregory Renza49% | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 03/26/2025 | Buy Now | — | Needham | Serge Belanger67% | $18 → $12 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert51% | $15 → $15 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | — | Leerink Partners | Roanna Ruiz37% | → $18 | Initiates | → Outperform | Get Alert |
| 03/05/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert51% | $15 → $15 | Maintains | Buy | Get Alert |
| 01/22/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert51% | $15 → $15 | Maintains | Buy | Get Alert |
| 01/13/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert51% | → $15 | Initiates | → Buy | Get Alert |
| 12/19/2024 | Buy Now | — | RBC Capital | Gregory Renza49% | $11 → $12 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | — | Needham | Serge Belanger67% | $10 → $18 | Maintains | Buy | Get Alert |
| 10/22/2024 | Buy Now | — | Truist Securities | Joon Lee77% | $12 → $17 | Maintains | Buy | Get Alert |
| 08/26/2024 | Buy Now | — | Rodman & Renshaw | Brandon Folkes43% | → $13 | Initiates | → Buy | Get Alert |
| 08/15/2024 | Buy Now | — | RBC Capital | Gregory Renza49% | $9 → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | — | Needham | Serge Belanger67% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2024 | Buy Now | — | Truist Securities | Joon Lee77% | $14 → $12 | Maintains | Buy | Get Alert |
| 06/19/2024 | Buy Now | — | Needham | Serge Belanger67% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | — | Needham | Serge Belanger67% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | — | Needham | Serge Belanger67% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | — | JMP Securities | Jason Butler51% | → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/13/2024 | Buy Now | — | RBC Capital | Gregory Renza49% | $10 → $9 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | — | Needham | Serge Belanger67% | $10 → $10 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | — | Truist Securities | Joon Lee77% | $18 → $14 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | — | Needham | Serge Belanger67% | $12 → $10 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | — | RBC Capital | Gregory Renza49% | $6 → $10 | Maintains | Outperform | Get Alert |
| 11/15/2023 | Buy Now | — | Truist Securities | Joon Lee77% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2023 | Buy Now | — | JMP Securities | Jason Butler51% | → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/10/2023 | Buy Now | — | RBC Capital | Gregory Renza49% | → $6 | Initiates | → Outperform | Get Alert |
| 08/08/2023 | Buy Now | — | Needham | Serge Belanger67% | $13 → $12 | Maintains | Buy | Get Alert |
| 06/21/2023 | Buy Now | — | Needham | Serge Belanger67% | → $13 | Reiterates | Buy → Buy | Get Alert |
| 05/19/2023 | Buy Now | — | JMP Securities | Jason Butler51% | $16 → $19 | Maintains | Market Outperform | Get Alert |
| 05/16/2023 | Buy Now | — | Needham | Serge Belanger67% | → $13 | Reiterates | Buy → Buy | Get Alert |
| 03/31/2023 | Buy Now | — | JMP Securities | Jason Butler51% | → $16 | Reiterates | → Market Outperform | Get Alert |
| 03/31/2023 | Buy Now | — | Needham | Serge Belanger67% | → $13 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | — | Needham | Serge Belanger67% | → $13 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | — | JMP Securities | Roy Buchanan39% | $14 → $16 | Maintains | Market Perform | Get Alert |
| 11/11/2022 | Buy Now | — | Needham | Serge Belanger67% | $12 → $13 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | — | Truist Securities | Joon Lee77% | $27 → $16 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | — | JMP Securities | Jason Butler51% | $19 → $14 | Maintains | Market Outperform | Get Alert |
| 08/09/2022 | Buy Now | — | Needham | Serge Belanger67% | $20 → $12 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cormedix (CRMD) stock?
The latest price target for Cormedix (NASDAQ:CRMD) was reported by Needham on June 24, 2025. The analyst firm set a price target for $20.00 expecting CRMD to rise to within 12 months (a possible 27.39% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cormedix (CRMD)?
The latest analyst rating for Cormedix (NASDAQ:CRMD) was provided by Needham, and Cormedix maintained their buy rating.
When was the last upgrade for Cormedix (CRMD)?
There is no last upgrade for Cormedix
When was the last downgrade for Cormedix (CRMD)?
There is no last downgrade for Cormedix.
When is the next analyst rating going to be posted or updated for Cormedix (CRMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cormedix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cormedix was filed on June 24, 2025 so you should expect the next rating to be made available sometime around June 24, 2026.
Is the Analyst Rating Cormedix (CRMD) correct?
While ratings are subjective and will change, the latest Cormedix (CRMD) rating was a maintained with a price target of $15.00 to $20.00. The current price Cormedix (CRMD) is trading at is $15.70, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
